成都科创板上市公司欧林生物 发布公告显示 公司在香港联交所主板上市的备案申请材料 11月12日晚间 欧林生物成立于2009年，是一家专注于人用疫苗研发、生产及销售企业，实现三款产品的商业化：吸附 破伤风疫苗、b型流感嗜血杆菌结合疫苗（或Hib结合疫苗）及A群C群脑膜炎球菌多糖结合疫苗（或AC 结合疫苗）。此外，公司还正在积极探索开发"超级细菌"——重组金黄色葡萄球菌疫苗研发，这是国际 上靶标组分最多且唯一进入Ⅲ期临床试验的同类疫苗。 2021年6月，公司成功在上交所科创板上市。上市以来，公司在首年即实现盈利，2022年-2024年公司营 收分别为5.47亿元、4.94亿元、5.86亿元；毛利分别为5亿元、4.6亿元、5.51亿元；期内利润分别为2658 万元、1144万元、1572万元。今年前三季度，营收为5.07亿元，同比增长31.11%；净利为4748万元。 对于赴港上市的原因，欧林生物表示，为加快公司的国际化战略及海外业务发展，增强公司的境外融资 能力，进一步提高公司的综合竞争力。同时，为有效拓展海外市场，提升国际影响力，推进公司长远战 略的实施，公司拟以自有资金出资不超过港币10000元，在香港设立全 ...

转自：成都日报锦观 上市申请获受理 成都"超级细菌"概念股冲刺港股IPO 1月12日晚，成都科创板上市公司欧林生物发布公告显示，公司在香港联交所主板上市的备案申请材 料，已于近日获中国证监会接收。这意味着，公司距离港股上市再进一步。 欧林生物成立于2009年，是一家专注于人用疫苗研发、生产及销售的企业，实现三款产品的商业化：吸 附破伤风疫苗、b型流感嗜血杆菌结合疫苗（或Hib结合疫苗）及A群C群脑膜炎球菌多糖结合疫苗（或 AC结合疫苗）。此外，公司还正在积极探索开发"超级细菌"——重组金黄色葡萄球菌疫苗研发，这是 国际上靶标组分最多且唯一进入Ⅲ期临床试验的同类疫苗。 在此背景下，成都正深化蓉港资本市场互联互通，成都企业奔赴港股市场的步伐也正在加快。随着科伦 博泰生物、茶百道等公司成功登陆港交所，来自成都的港股上市公司已达29家。此外，极米科技、天味 食品等一批生物医药、高新科技、食品消费类企业正计划通过"A+H"战略走向更广阔的市场。在港上市 的"成都军团"有望随之扩容。 成都日报锦观新闻记者 刘泰山 2021年6月，公司成功在上交所科创板上市。上市以来，公司在首年即实现盈利，2022—2024年营收分 别为 ...

证券日报网讯1月5日，沃森生物（300142）在互动平台回答投资者提问时表示，目前公司共有8个自主 疫苗产品(14个品规)正式上市销售，包括：13价肺炎结合疫苗(西林瓶型和预灌封型)、双价HPV疫苗(西 林瓶型和预灌封型)、23价肺炎多糖疫苗(西林瓶型和预灌封型)、b型流感嗜血杆菌结合疫苗(西林瓶型和 预灌封型)、A群C群脑膜炎球菌多糖结合疫苗(西林瓶型和预灌封型)、ACYW135群脑膜炎球菌多糖疫苗 (西林瓶型和预灌封型)、A群C群脑膜炎球菌多糖疫苗(西林瓶型)和吸附无细胞百白破联合疫苗(西林瓶 型)。上述疫苗产品主要用于预防由特定病原微生物感染所引起的相关疾病。公司将持续狠抓产品营销 工作，制定切实可行的策略和执行措施，加强人才队伍建设，以科学普及为助力，坚定信心，强化落 实，努力加强和巩固终端渠道的覆盖率和渗透率，为公司和股东创造价值。 ...

Core Viewpoint - Oulin Biotech is facing a lawsuit involving a contract dispute with an individual, Wang Jianhua, over a total amount of 19.2 million yuan, which includes penalties and is currently under court proceedings [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Wang Jianhua is entitled to a commission of 16 million yuan for providing technical materials related to specific vaccines, along with a penalty of 3.2 million yuan calculated at 20% of the commission [3]. - Oulin Biotech has acknowledged receipt of the legal documents and asserts that the claims lack sufficient factual and legal basis, thus rejecting the plaintiff's demands [3][4]. Group 2: Financial Impact - The court has frozen 1 non-basic bank account of the company, with the frozen amount of 19.2 million yuan representing 2.06% of the company's latest audited net assets and 8.57% of its cash balance, indicating a relatively minor impact on daily operations [4]. - The company reported a revenue of 589 million yuan in 2024, marking an 18.69% year-on-year increase, and a net profit of 20.76 million yuan, up 18.24% from the previous year [5]. Group 3: Company Background - Oulin Biotech specializes in the research, production, and sales of human vaccines and was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in June 2021 [5]. - The company has only three commercialized products and has experienced significant profit declines in 2022 and 2023, with net profits dropping by 75.38% and 33.94%, respectively [5].

Core Viewpoint - Oulin Bio (688319) is facing a lawsuit regarding a contract dispute with individual Wang Jianhua, involving a total claim amount of 19.2 million yuan, which includes penalties but excludes litigation costs [1][2]. Group 1: Lawsuit Details - The lawsuit stems from a contract signed in 2011, where the plaintiff claims to have fulfilled obligations by providing two vaccine technologies and is thus entitled to a commission [1]. - Wang Jianhua's claims include a request for 16 million yuan in product commissions, 3.2 million yuan in penalties, and coverage of all litigation costs [1]. Group 2: Company Response - Oulin Bio has acknowledged receipt of legal documents and asserts that the plaintiff's claims lack sufficient factual and legal basis, thus rejecting the claims [2]. - The company emphasizes that the products involved in the lawsuit are legally marketed and compliant with relevant laws and regulations, indicating no significant adverse impact on its operations [2]. Group 3: Financial Impact - The court has frozen one non-basic bank account with a total of 19.2 million yuan, which represents 2.06% of the company's latest audited net assets and 8.57% of its cash balance, indicating a relatively minor impact on daily operations [2]. - The lawsuit's financial implications remain uncertain until the court reaches a decision, and the company will handle financial reporting in accordance with accounting standards [3]. Group 4: Commitment to Compliance - Oulin Bio, as an innovative technology company, emphasizes its commitment to intellectual property compliance and the regulation of technology cooperation, stating that all R&D activities adhere to legal requirements [3].

Core Viewpoint - Oulin Biotech's stock has shown significant volatility, with a year-to-date increase of 136.79% and a recent decline of 2.03% on December 2, 2023, indicating fluctuating investor sentiment in the biotech sector [1] Company Performance - Oulin Biotech reported a revenue of 507 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 31.11% [2] - The net profit attributable to the parent company reached 47.48 million yuan, marking a substantial increase of 1079.36% compared to the previous year [2] - The company has distributed a total of 15.43 million yuan in dividends since its A-share listing [3] Stock Market Activity - As of December 2, 2023, Oulin Biotech's stock price was 25.10 yuan per share, with a market capitalization of 10.189 billion yuan [1] - The stock has experienced a trading volume of 49.39 million yuan with a turnover rate of 0.48% [1] - The stock has appeared on the "龙虎榜" (Dragon and Tiger List) twice this year, with the most recent occurrence on August 20 [1] Shareholder Information - As of September 30, 2025, Oulin Biotech had 10,200 shareholders, an increase of 56.42% from the previous period [2] - The average number of circulating shares per shareholder decreased by 36.07% to 39,746 shares [2] - Notable institutional shareholders include 兴全合润混合A and 兴全合宜混合A, with stable holdings compared to the previous period [3]

Core Viewpoint - Company Olin Bio (688319.SH) has submitted an application for a mainboard listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, aiming to leverage its strong market position in the vaccine sector [1][2] Group 1: Company Overview - Olin Bio is a biopharmaceutical company focusing on unmet medical needs in "super bacteria vaccines" and "adult vaccines" [2] - The company has three commercialized products: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine [2] - Olin Bio's Tetanus Toxoid Vaccine holds over 80% market share in China as of 2024 [2] Group 2: Financial Performance - Revenue for Olin Bio during the reporting period (2022-2025) was 5.47 billion, 4.94 billion, 5.86 billion, and 3.05 billion respectively, showing significant fluctuations [4] - The annual profit and total comprehensive income were 26.58 million, 11.44 million, 15.72 million, and 13.23 million respectively, with 2023 and 2024 figures lower than 2022 [4] - Gross profit margins were consistently high at 92.3%, 93.1%, 94%, and 92.3% over the same period [4] Group 3: Revenue Sources - A significant portion of Olin Bio's revenue comes from the Tetanus Toxoid Vaccine, contributing approximately 4.377 billion, 4.63 billion, 5.358 billion, and 2.683 billion during the reporting period, accounting for around 80% to 93.7% of total revenue [5]

Core Viewpoint - The article discusses the IPO application of Olin Biotech (688319.SH) for listing on the Hong Kong Stock Exchange, highlighting its commercialized products and market position in the vaccine sector [1][2][5]. Group 1: Company Overview - Olin Biotech is a biopharmaceutical company focusing on unmet medical needs in "super bacteria vaccines" and "adult vaccines" [5]. - The company has three commercialized products: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine [5][6]. Group 2: Market Position and Financial Performance - Olin Biotech's Tetanus Toxoid Vaccine holds over 80% market share in China as of 2024 [2][6]. - Revenue projections for 2024 are estimated at 586 million yuan, with significant contributions from the Tetanus Toxoid Vaccine, which accounted for approximately 87.9% of total revenue in the first half of 2025 [10]. - The company reported revenues of 547 million yuan, 494 million yuan, and 586 million yuan for 2022, 2023, and 2024 respectively, with a notable fluctuation in annual profits [9]. Group 3: Sales Network and Growth - As of November 18, Olin Biotech's sales network covers 30 provinces and municipalities in China, with over 2,000 direct commercial relationships established with district and county-level disease control centers [6]. - The company has supplied its vaccines to approximately 8,100 vaccination points across the country, including around 2,400 general hospitals [6]. Group 4: Shareholding Structure - After its A-share listing, Shanghai Wushan became the largest shareholder of Olin Biotech, holding approximately 14.83% of the issued share capital [7].

Core Viewpoint - Oulin Biotech's stock has experienced significant fluctuations, with a year-to-date increase of 135.66% and a recent decline in trading performance, indicating potential volatility in the market [1][2]. Company Overview - Oulin Biotech, established on December 11, 2009, and listed on June 8, 2021, is located in Chengdu, Sichuan Province. The company specializes in the research, production, and sales of human vaccines [1]. - The main revenue sources for Oulin Biotech include: Tetanus vaccine (90.99%), A and C group meningococcal polysaccharide conjugate vaccine (4.49%), Haemophilus influenzae type b conjugate vaccine (3.99%), and others (0.47%) [1]. Financial Performance - For the period from January to September 2025, Oulin Biotech reported a revenue of 507 million yuan, reflecting a year-on-year growth of 31.11%. The net profit attributable to the parent company was approximately 47.48 million yuan, showing a substantial increase of 1079.36% [2]. - Since its A-share listing, Oulin Biotech has distributed a total of 15.43 million yuan in dividends [3]. Shareholder Information - As of September 30, 2025, Oulin Biotech had 10,200 shareholders, an increase of 56.42% from the previous period. The average number of circulating shares per shareholder was 39,746, a decrease of 36.07% [2]. - Among the top ten circulating shareholders, notable positions include: Xingquan Helun Mixed A (holding 15.44 million shares), Xingquan Heyi Mixed A (holding 8.92 million shares), and Xingquan Commercial Model Mixed (LOF) A (holding 4.64 million shares, a new entry) [3].

Core Viewpoint - Oulin Bio has experienced a significant stock price increase, with a 12.88% rise over the past three days, indicating strong market interest and potential investor confidence in the company's performance [1]. Company Overview - Oulin Bio, established on December 11, 2009, and listed on June 8, 2021, is located in Chengdu, Sichuan Province. The company specializes in the research, production, and sales of human vaccines [1]. - The main revenue sources for Oulin Bio include: - Tetanus vaccine: 90.99% - A and C group meningococcal polysaccharide conjugate vaccine: 4.49% - Haemophilus influenzae type b conjugate vaccine: 3.99% - Other (supplementary): 0.47% - Refined tetanus toxin raw liquid: 0.07% [1]. Fund Holdings - Oulin Bio is a significant holding for the Dongfang Urban Consumption Theme Mixed Fund (006235), which held 60,300 shares, accounting for 5.93% of the fund's net value, making it the largest position [2]. - The fund has realized a floating profit of approximately 74,700 yuan today and a total of 166,900 yuan during the three-day price increase [2]. Fund Manager Performance - The fund manager Wang Ran has a tenure of 10 years and 215 days, with a total fund size of 20.4 million yuan. The best return during his tenure is 68.26%, while the worst is -58.67% [3]. - Co-manager Cai Shangjun has been in position for 1 year and 281 days, managing a fund size of 2.76453 million yuan, with a best return of -0.48% and a worst return of -1.17% during his tenure [3].